Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 17/20 | 0.52 |
| ▸ | CCR3 | P51677 | 17/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1929370 | 0.87 | HRH1 (0.60) | HRH1CCR3KCNH2 | |
| SCHEMBL5369447 | 0.81 | HRH1 (0.56) | HRH1CCR3KDM4EKCNH2SLC6A2 | |
| SCHEMBL14715736 | 0.80 | HRH1 (0.50) | HRH1CCR3KDM4EKCNH2 | |
| SCHEMBL14715703 | 0.80 | HRH1 (0.50) | HRH1CCR3KDM4EKCNH2 | |
| SCHEMBL5102799 | 0.79 | HRH1 (0.59) | HRH1CCR3KDM4EKCNH2SLC6A2 | |
| SCHEMBL5369784 | 0.77 | HRH1 (0.53) | HRH1CCR3KDM4EKCNH2 | |
| SCHEMBL5469425 | 0.76 | SLC6A2 (0.56) | HRH1CCR3KDM4EKCNH2SLC6A2 | |
| SCHEMBL5367457 | 0.76 | HRH1 (0.52) | HRH1CCR3KDM4EKCNH2 | |
| SCHEMBL5364002 | 0.76 | CCR3 (0.53) | HRH1CCR3KCNH2 | |
| SCHEMBL3965013 | 0.76 | CCR3 (0.54) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478624-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-08 | — | — | EP | disclosed |
| EP-1478624-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-08 | — | — | EP | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1478624-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | HRH1 33/4885CCR3 2/4885KDM4E 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.